Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Breast Neoplasms 303Carcinoma, Non-Small-Cell Lung 240Prostatic Neoplasms 196Neoplasms 190Lung Neoplasms 149Multiple Myeloma 141Neoplasm Metastasis 110Colorectal Neoplasms 104Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 82Pancreatic Neoplasms 76Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 69Carcinoma, Renal Cell 67Squamous Cell Carcinoma of Head and Neck 62Lymphoma, Non-Hodgkin 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 60Urinary Bladder Neoplasms 58Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Recurrence 54Glioblastoma 53Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Endometrial Neoplasms 50Stomach Neoplasms 46Sarcoma 46

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Hypereosinophilic Syndrome × 90 days × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡